Open an account

Pulse Biosciences

PLSE · NASDAQ

$50.84+$3.29 (+6.92%)TodayMarket closed ·
Prev close $47.55

About PLSE

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 116 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.

Employees
116
Headquarters
Hayward, California
Listed
May 18, 2016
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
pulsebiosciences.com

PLSE key statistics

Market cap
3.46B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
455.00K
Volume
386.03K
Open price
$47.25
High today
$52.33
Low today
$47.25
52 Week high
$58.90
52 Week low
$12.56

Pulse Biosciences (PLSE) at a glance

As of Oct 20, 2026, Pulse Biosciences (PLSE) shares are priced at $50.84, giving the company a market cap of 3.46B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $47.25 and $52.33. The current price is 7.6% above the day's low and 2.8% below its high.

Volume so far is 386.03K shares, in line with the average of 455.00K shares a day.

Over the past year Pulse Biosciences has ranged from $12.56 to $58.90, and now sits 83% of the way up that range.

Pulse Biosciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.36 per share against an estimate of -$0.3672.

The average analyst price target is $55.08, 8.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $55.08
Low
$35.35
Now
$50.84
High
$76.65

PLSE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 15.6% on average.

  1. Q3 FY24: reported -$0.16 per share against an estimate of $0.00
  2. Q4 FY24: reported -$0.17 per share against an estimate of $0.00
  3. Q1 FY25: reported -$0.17 per share against an estimate of $0.00
  4. Q2 FY25: reported -$0.20 per share against an estimate of -$0.2652
  5. Q3 FY25: reported -$0.29 per share against an estimate of -$0.3162
  6. Q4 FY25: reported -$0.26 per share against an estimate of -$0.3162
  7. Q1 FY26: reported -$0.24 per share against an estimate of -$0.3213
  8. Q2 FY26: reported -$0.36 per share against an estimate of -$0.3672

PLSE news

  • Press releaseBusiness Wire

    Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

  • Press releaseBusiness Wire

    Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

  • Press releaseBusiness Wire

    Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

  • Press releaseBusiness Wire

    Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

  • Press releaseBusiness Wire

    Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.